Internal Medicine, Hematology & Oncology · Anderson, SC
NPI
1427275437
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
2000 E Greenville St, Cancer Center 3rd Floor
Anderson, SC, 29621
Phone (864) 512-4580
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.5M
153,561 services
Medicare patients, 2024
376
Average age 75
Drug cost, 2024
$4.3M
1,853 prescriptions
Company payments, 2025
$1,176
From 31 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jay B Nayak was code J9271 (injection, pembrolizumab, 1 mg), 19,400 times for 13 patients. In total Jay B Nayak billed 153,561 services in 123 codes, and Medicare paid $3.5M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-02-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 19,400 | 13 | $44.72 | $868K |
| Q5101 Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 19,380 | 11 | $0.27 | $5,260 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 13,600 | 93 | $15.76 | $214K |
| J0897 Injection, denosumab, 1 mg | Office | 13,260 | 33 | $20.65 | $274K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 8,100 | 12 | $0.11 | $880 |
| 85025 Blood Count | Office | 1,247 | 332 | $7.59 | $9,462 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,090 | 21 | $0.73 | $799 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,080 | 26 | $0.09 | $97.78 |
| 80053 Clinical Chemistry | Office | 897 | 242 | $10.31 | $9,249 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 644 | 289 | $12.68 | $8,163 |
| 99215 Office E&M - Established | Office | 616 | 140 | $138.63 | $85K |
| 99214 Office E&M - Established | Office | 450 | 241 | $90.86 | $41K |
| 83540 Clinical Chemistry | Office | 409 | 184 | $6.32 | $2,587 |
| 82728 Clinical Chemistry | Office | 409 | 183 | $13.36 | $5,464 |
| 83550 Clinical Chemistry | Office | 405 | 182 | $8.55 | $3,462 |
By year: 2022 $401K for 23,376 services; 2023 $3.3M for 174,445 services; 2024 $3.5M for 153,561 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,247 | 332 | $7.59 | $9,462 |
| 80053 Clinical Chemistry | 897 | 242 | $10.31 | $9,249 |
| 83540 Clinical Chemistry | 409 | 184 | $6.32 | $2,587 |
| 82728 Clinical Chemistry | 409 | 183 | $13.36 | $5,464 |
| 83550 Clinical Chemistry | 405 | 182 | $8.55 | $3,462 |
| 36415 Venipuncture Blood Collection | 307 | 143 | $8.60 | $2,640 |
| 82607 Clinical Chemistry | 186 | 113 | $14.71 | $2,736 |
| 82378 Clinical Chemistry | 132 | 34 | $18.58 | $2,453 |
| 86300 Immunoassay | 111 | 48 | $20.39 | $2,263 |
| 83615 Clinical Chemistry | 91 | 50 | $5.85 | $533 |
Medicare prescription drug claims, 2024
In 2024, the drug Jay B Nayak prescribed most often to Medicare patients was Anastrozole, with 207 prescriptions and refills. In total Jay B Nayak wrote 1,853 Medicare prescriptions that cost $4.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 207 | 503 | 56 | $4,145 |
| Eliquis Apixaban | 122 | 146 | 18 | $83K |
| Ondansetron Hcl Generic | 101 | 102 | 54 | $538 |
| Prednisone Generic | 81 | 97 | 20 | $496 |
| Hydroxyurea Generic | 60 | 109 | 11 | $1,774 |
| Levothyroxine Sodium Generic | 56 | 108 | 12 | $699 |
| Dexamethasone Generic | 55 | 60 | 23 | $787 |
| Olanzapine Generic | 48 | 48 | 25 | $312 |
| Orgovyx Relugolix | 47 | 47 | Under 11 | $124K |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 44 | 44 | 37 | $673 |
| Abiraterone Acetate Generic | 43 | 45 | Under 11 | $137K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 40 | 40 | 16 | $489 |
| Xtandi Enzalutamide | 36 | 36 | Under 11 | $493K |
| Acyclovir Generic | 34 | 34 | Under 11 | $236 |
| Methylprednisolone Generic | 34 | 34 | 28 | $231 |
Brand drugs: 447 claims; generic drugs: 1,406 claims; opioid claims: 97.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jay B Nayak $1,176 ($1,176 in general payments such as food, travel and fees) from 31 companies. The largest payer was Novartis Pharmaceuticals Corporation with $149.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 6 | $149 |
| Galvanize Therapeutics, Inc | 1 | $98.1 |
| Celgene Corporation BMY | 4 | $86.66 |
| Abbvie Inc. ABBV | 4 | $73.95 |
| Genentech USA, Inc. ROG.SW | 1 | $53.45 |
| GlaxoSmithKline, LLC. GSK | 3 | $50.19 |
| Boston Scientific Corporation BSX | 1 | $48.67 |
| SpringWorks Therapeutics, Inc. | 2 | $43.19 |
| Eisai Inc. 4523.T | 2 | $42.57 |
| Gilead Sciences, Inc. GILD | 2 | $37.4 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.